Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

In a phase II study conducted in Japan, oral fludarabine phosphate administered to patients with B-cell non-Hodgkin’s lymphoma was shown to have an overall response rate of 65%, but with significant, albeit manageable, hematologic toxicity. Oral administration of this drug may prove a convenient alternative to the current regimens which call for several clinic or infusion center visits in the week of therapy.

Oral Fludarabine for Indolent NHL: A Phase II Trial